OneSource-Hikma partnership secures approval to commercialise generic version of Ozempic in Saudi Arabia
Kiran DSIJCategories: Mindshare, Trending
OneSource with its development capabilities, industry-leading manufacturing capacities and strong compliance track record, has won the trust of global pharmaceutical companies seeking efficient, end-to-end solutions.
OneSource Speciality Pharma Limited has secured approval from the Saudi Food and Drug Authority (SFDA) for its generic version of Ozempic® (semaglutide). This regulatory milestone marks the company's entry into the Kingdom of Saudi Arabia, a critical market for GLP-1 therapies. Through an exclusive partnership with Hikma Pharmaceuticals PLC, OneSource intends to commercialise the product across the Middle East and North Africa (MENA) region. The collaboration aims to address the rising demand for semaglutide by providing a high-quality, affordable generic alternative to patients in these markets.
The operational framework of this agreement leverages OneSource’s manufacturing capabilities and Hikma’s established regional presence. OneSource will produce the semaglutide at its integrated Biologics and Drug-Device Combination facility located in Bengaluru, India. Hikma, recognised as the largest pharmaceutical entity in the MENA region by sales, will utilise its extensive distribution networks and institutional relationships to manage the commercial rollout. This strategy is designed to scale access effectively across both private and institutional healthcare channels throughout the region.
About OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products, including biologics, drug-device combinations, sterile injectables and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry-leading manufacturing capacities and strong compliance track record, has won the trust of global pharmaceutical companies seeking efficient, end-to-end solutions.
Disclaimer: The article is for informational purposes only and not investment advice.